中文版 | English
Title

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

Author
Corresponding AuthorLiu, Yingxia; Liu, Lei
Publication Years
2020-10-01
DOI
Source Title
ISSN
2095-8099
EISSN
2096-0026
Volume6Issue:10
Abstract

There is currently an outbreak of respiratory disease caused by a novel coronavirus. The virus has been named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the disease it causes has been named coronavirus disease 2019 (COVID-19). More than 16% of patients developed acute respiratory distress syndrome, and the fatality ratio was 1%-2%. No specific treatment has been reported. Herein, we examined the effects of favipiravir (FPV) versus lopinavir (LPV)/ritonavir (RTV) for the treatment of COVID-19. Patients with laboratory-confirmed COVID-19 who received oral FPV (Day 1: 1600 mg twice daily; Days 2-14: 600 mg twice daily) plus interferon (IFN)-alpha by aerosol inhalation (5 million international unit (IU) twice daily) were included in the FPV arm of this study, whereas patients who were treated with LPV/RTV (Days 1-14: 400 mg/100 mg twice daily) plus IFN-alpha by aerosol inhalation (5 million IU twice daily) were included in the control arm. Changes in chest computed tomography (CT), viral clearance, and drug safety were compared between the two groups. For the 35 patients enrolled in the FPV arm and the 45 patients in the control arm, all baseline characteristics were comparable between the two arms. A shorter viral clearance median time was found for the FPV arm versus the control arm (4 d (interquartile range (IQR): 2.5-9) versus 11 d (IQR: 8-13), P < 0.001). The FPV arm also showed significant improvement in chest CT compared with the control arm, with an improvement rate of 91.43% versus 62.22% (P = 0.004). After adjustment for potential confounders, the FPV arm also showed a significantly higher improvement rate in chest CT. Multivariable Cox regression showed that FPV was independently associated with faster viral clearance. In addition, fewer adverse events were found in the FPV arm than in the control arm. In this open-label before-after controlled study, FPV showed better therapeutic responses on COVID-19 in terms of disease progression and viral clearance. These preliminary clinical results provide useful information of treatments for SARS-CoV-2 infection. (c) 2020 THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Keywords
URL[Source Record]
Indexed By
Language
English
Funding Project
National Science and Technology Major Project[
WOS Research Area
Engineering
WOS Subject
Engineering, Multidisciplinary
WOS Accession No
WOS:000616414700021
Publisher
Important Publications
ESI Highly Cited Papers ; ESI Hot Papers ; ESI Hot Papers ; ESI Hot Papers ; ESI Hot Papers ; ESI Hot Papers ; ESI Hot Papers ; ESI Hot Papers ; ESI Hot Papers ; ESI Hot Papers ; ESI Hot Papers
SUSTech Authorship
First ; Corresponding
Data Source
Web of Science
Citation statistics
Cited Times [WOS]:416
Document TypeJournal Article
Identifierhttps://kc.sustech.edu.cn/handle/2SGJ60CL/221068
DepartmentThe Third People's Hospital of Shenzhen
Affiliation
1.Southern Univ Sci & Technol, Affiliated Hosp 2, Peoples Hosp Shenzhen 3, Natl Clin Res Ctr Infect Dis, Shenzhen 518100, Peoples R China
2.Beijing Inst Pharmacol & Toxicol, Natl Engn Res Ctr Emergence Drugs, Beijing 100850, Peoples R China
First Author AffilicationThe Third People's Hospital of Shenzhen
Corresponding Author AffilicationThe Third People's Hospital of Shenzhen
First Author's First AffilicationThe Third People's Hospital of Shenzhen
Recommended Citation
GB/T 7714
Cai, Qingxian,Yang, Minghui,Liu, Dongjing,et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study[J]. ENGINEERING,2020,6(10).
APA
Cai, Qingxian.,Yang, Minghui.,Liu, Dongjing.,Chen, Jun.,Shu, Dan.,...&Liu, Lei.(2020).Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study.ENGINEERING,6(10).
MLA
Cai, Qingxian,et al."Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study".ENGINEERING 6.10(2020).
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Export to Excel
Export to Csv
Altmetrics Score
Google Scholar
Similar articles in Google Scholar
[Cai, Qingxian]'s Articles
[Yang, Minghui]'s Articles
[Liu, Dongjing]'s Articles
Baidu Scholar
Similar articles in Baidu Scholar
[Cai, Qingxian]'s Articles
[Yang, Minghui]'s Articles
[Liu, Dongjing]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Cai, Qingxian]'s Articles
[Yang, Minghui]'s Articles
[Liu, Dongjing]'s Articles
Terms of Use
No data!
Social Bookmark/Share
No comment.

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.